Counterfeit Drugs Proliferate on Internet
Posted on: Monday, 21 July 2008, 03:00 CDT
The U.S. Food and Drug Administration has been struggling as it tries to deal with rogue Internet sites that sell medications, a researcher says.
Francis Palumbo of the University of Maryland School of Pharmacy, the author of the report, Policy Implications of Drug Importation, said U.S. consumers face a growing risk of getting counterfeit drugs because of rising Internet sales of medical drugs -- projected to reach upwards of $75 billion by 2010.
When consumers buy from those, it is definitely buyer beware. They are often not licensed anywhere we are aware of, Palumbo said in a statement.
The U.S. Food and Drug Administration has been pulling its hair out over the years trying to deal with rogue Internet sites, the terminology they (FDA) use, he said.
During the past 10 years, many people have been importing prescription drugs that were available for purchase in the United States and justifying the foreign purchases based on the FDA's policy of personal use exemption, Palumbo said.
The policy was never intended to allow this practice to be institutionalized, the report says.
The report concludes that both FDA and U.S. Customs officials can't handle the volume of medication entering the country.
The report is published in the journal Clinical Therapeutics.
Source: United Press International
Related Articles
- XDx's AlloMap(R) Gene Expression Test Cleared By U.S. Food and Drug Administration (FDA)
- Commenting on the U.S. Food and Drug Administration (FDA) Early Communication, Allergan Clarifies FDA's Inquiry Relates Primarily to High Dose Medical Uses of BOTOX(R), Rather Than BOTOX(R) Cosmetic for Aesthetic Use
- TyRx Pharma, Inc. Announces Food and Drug Administration (FDA) 510(K) Clearance of the AIGIS(Rx)(TM) Cardiac Rhythm Medical Device (CRMD) Anti-Bacterial Envelope, an Innovative Mesh Envelope Designed to Immobilize and Reduce Bacterial Infection of a Pacem
- TYZEKA(TM) (Telbivudine) Approved By U.S. Food and Drug Administration (FDA) As a New Treatment for Patients With Chronic Hepatitis B
- eRx Collaborative Boosts Patient Safety With 8,000 Prescriptions Changed in June; Record Number of Electronic Prescriptions Changed As a Result of Drug-Drug and Drug-Allergy Alerts
- U.S. Food and Drug Administration (FDA) Approves ATRIPLA(TM) (Efavirenz 600 Mg/ Emtricitabine 200 Mg/ Tenofovir Disoproxil Fumarate 300 Mg), The First Once-Daily Single Tablet Regimen for Adults With HIV-1 Infection
- Chemical Heritage Foundation (CHF) and the Food and Drug Administration (FDA) Will Cosponsor FDA Centennial Conference at CHF on Tuesday, 16 May 2006
- Genelabs Updates Development Options for Its Investigational Lupus Drug After FDA Meeting
- U.S. Food and Drug Administration (FDA) Approves BARACLUDE(TM) (Entecavir) for Treatment of Chronic Hepatitis B
- Pulling of MS Drug Calls FDA Actions into Question
User Comments (0)
RSS Feeds